Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Executive Summary
The move to deny coverage for an approved orphan drug is ‘highly unusual,' NORD VP says. 'We certainly hope this isn’t going to set a precedent.'
You may also be interested in...
Lower Drug Costs Might End Perception US FDA Approval Standards Are Lower
CDER Director Woodcock says pricing and approval issues are becoming "conflated" but it is hard to change people's minds when they are "determinedly angry about something."
CMS Reminds State Medicaid Agencies: Accelerated Approval Is Still Full Approval
States are eager to try more aggressive methods to rein in prescription drug costs under Medicaid, and CMS is willing to be flexible in permitting innovative contracting. But the agency is also quietly but firmly making clear that all FDA-approved drugs have to be treated the same.
Orphan Drug Pricing Heading To Negotiating Table in US?
The Institute for Clinical and Economic Review is launching an initiative to adapt its value assessment approach to orphan and ultra-orphan drugs, including a possible consideration of what should be a fair return on investment for manufacturers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: